van Houte Hans 4

What Happened

• Hans van Houte, Chief Financial Officer of Nurix Therapeutics (NRIX), had restricted stock units (RSUs) convert/exercise into shares (derivative code M) totaling 11,496 shares on 2026-01-30 at $0.00 per share. On the same date he sold 3,661 shares in open-market transactions for aggregate proceeds of approximately $60,766.
• The sales were routine "sell-to-cover" transactions to satisfy tax withholding obligations associated with the RSU vesting; they are not described as discretionary open-market trades by the reporting person.

Key Details

• Transaction date: 2026-01-30.
• RSU/derivative conversions: 2,887 + 2,000 + 3,750 + 2,859 = 11,496 shares acquired (exercise/convert at $0.00).
• Open-market sales: 3,588 shares at a weighted avg $16.58 (total ~$59,498; price range $16.33–$17.32) and 73 shares at a weighted avg $17.37 (total ~$1,268; price range $17.33–$17.49). Total proceeds ≈ $60,766.
• Notable footnotes: F1 — sales were mandated sell-to-cover for tax withholding; F4–F9 — RSUs represent contingent rights to common stock with specified vesting schedules. F2/F3 provide sale price ranges and weighted averages.
• Filing timeliness: Reported on 2026-01-30 for the same transaction date — no late filing indicated in the provided data.
• Shares owned after the transaction: Not specified in the excerpt provided.

Context

• The M code indicates conversion/exercise of derivatives (here, RSUs converting to common stock). Because some or all of the newly issued shares were sold to cover taxes (sell-to-cover), this is a routine tax-related transaction rather than an independent investment decision. Such sell-to-cover trades are common after RSU vesting and do not necessarily signal insider sentiment about the stock.